V. MANNA, M.T. DANIELE, M. PINTO - Vol. 9, March 2003, Issue 1
Testo Bibliografia Summary Indice
Disedonia. Ruolo della disregolazione omeostatica
edonica nelle dipendenze patologiche da sostanze
ed in altri disturbi psico-patologici
Dyshedonia. Role of hedonic homeostatic dysregulation in drug addictions
and in other psychopathological disorders
1 Ribot J. La psychologie des sentiments. Paris: Felix Alcan 1896.
2 Bleuler E. Dementia praecox and the group of schizophrenias. New York: International University Press 1950. (original work published 1911).
3 Kraepelin E. Dementia praecox and paraphrenia. Edimburgh: Livingstone 1919. (original work published 1913).
4 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Third Edition, Revised, (DSM-III-R). Washington D.C.: American Psychiatric Press 1987.
5 Ettenberg A. Anhedonia. In: Costello CG, ed. Symptoms of schizophrenia. New York: Wiley 1993.
6 American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). Washington D.C.: American Psychiatric Press 1994.
7 Argyropoulos SV, Nutt DJ. Anhedonia and chronic mild stress model in depression. Psychopharmacology 1997;134:333-6.
8 Ljungberg T, Apicella P, Shultz W. Response of monkey e neurons during delayed alternation performance. J Neurophysiol 1992;67:145-63.
9 Willner P, Klimek V, Golembiowska K, Muscat R. Changes in mesolimbic dopamine may explain stress-induced anhedonia. Psychobiology 1991;19:79-84.
10 Koob GF, Le Moal M. Drug Abuse: Hedonic Homeostatic Dysregulation. Science 1997;278:52-8.
11 Crow TJ. Catecholamine-containing neurones and electrical self-stimulation: a review of some data. Psychol Med 1972;2:414-21.
12 German DC, Bowden DM. Catecholamine systems as neural substrate of intracranial self-stimulation: a hypothesis. Brain Res 1974;73:381-419.
13 Lippa AS, Antleman S, Fisher A, Canfield D. Neurochemical mediation of "reward": a significant role for dopamine. Pharmacol Biochem Behav 1973;1:25-8.
14 Wise RA. The anhedonia hypothesis: mark III. Behav Brain Sci 1985;8:178-86.
15 Wise RA, Spindler J, de Witt H, Gerberg GJ. Neuroleptic induced "anhedonia" in rats: pimozide blocks "reward" quality of food. Science 1978;201:262-4.
16 Wise RA. Neuroleptics and operant behavior: the anhedonia hypothesis. Behav Brain Sci 1982;5:39-87.
17 Xenakis S, Sclafani A. The dopaminergic mediation of a sweet "reward" in normal and VMH hyperphagic rats. Pharmacol Biochem Behav 1982;16:293-302.
18 Blackburn JR, Phillips AG, Jakubovic A, Fibiger A. Dopamine and preparatory behavior: II. A neurochemical analysis. Behav Neurosci 1989;103:15-23.
19 Simansky KJ, Bourbonais KA, Smith GP. Food-related stimuli increase the ratio of 3,4-dhydroxyphenilacetic acid to dopamine in the hypothalamus. Pharmacol Biochem Behav 1985;23:253-8.
20 Di Ciano P, Blaha CD, Phillips AG. Conditioned changes in dopamine oxidation currents in the nucleus accumbens of rats by stimuli paired with self-administration or joked-administration of d-amphetamine. Europ J Neurosci 1998;10:1121-7.
21 Kiyatkin EA, Wise RA, Gratton A. Drug and behavior-associated changes in related electro-chemical during intravenous heroin self-administration in rats. Synapse 1993;14:60-72.
22 Di Chiara G. The role of dopamine in drug abuse viewed from the prospective of its role in motivation. Drug and Alcohol Dependence 1995;38:95-137.
23 Di Chiara G. A motivational learning hypothesis of the role of mesolimbic dopamine in compulsive drug use. J Psychopharmacol 1998;12:54-67.
24 Clarke SN, Parker LA. Morphine-induced modification of quinine palatability: effects of multiple morphine-quinine trials. Pharmacology, Biochemistry and Behavior 1995;51:505-8.
25 Welch CC, Kim EM, Grace MK, Billington CJ, Levin AS. Palatability induced hyperphagia increase hypotalamic dynorphine peptide and mRNA levels. Brain Res 1996;721:126-31.
26 Berridge KC, Pecina S. Benzodiazepines, appetite and taste palatability. Neurosci Bio-behav Rev 1985;9:5-19.
27 Berridge KC. Food reward: brain substrates of wanting and liking. Neurosci Bio-behav Rev 1996;20:1-25.
28 Mayberg HS, Robinson RG, Wong DF, Parikh R, Bolduc P. PET imaging of cortical S2 receptors after stroke: literalised changes and relationship to depression. Am J Psychiatry 1988;145:937-43.
29 Simon H, Le Moal M, Calas A. Efferents and afferents of the ventral tegmental A10 region studied after local injection of 3H-leucine and horse radish peroxidase. Brain Res 1979;178:17-40.
30 Fritze J, Beckman H. The cholinergic agonist RS86: a pharmacopsychological study. Neuropsychobiology 1988;19:35-9.
31 Sano M. Basal ganglia deseases and depression. Neuropsychol Behav Med 1991;4:41-8.
32 Ebmeir K, Ebert D. Imaging functional change and dopaminergic activity in depression In: Beniner RJ, Palomo T, Archer T, eds. Dopamine disease state. Madrid: Fundacion Cerebro Y Mente 1996.
33 Frecska E, Arato M, Banki CM, Mohar K, Perenyi A, Bagdy G, et al. Prolactin response to fentanyl in depression. Biol Psychiatry 1989;25:692-6.
34 Papp M, Lappas S, Muscat R, Willner P. Attenuation of place preference conditioning, but not place avversion conditioning by chronic mild stress. J Psychopathol 1992;6:352-6.
35 Berridge KC, Robinson TE. What is the role of dopamine in reward: hedonic impact, reward learning or incentive salience? Brain Res Rev 1998:309-69.
36 Berger SP, Hall S, Mickalian JD, Reid MS, Crawford CA, Delucchi K, et al. Haloperidol antagonism of cue-elicited cocaine craving. Lancet 1996;347:504-8.
37 Brauer LH, Goudie AJ, de Wit H. Dopamine ligands and the stimulus effects of amphetamine: animal models versus human laboratory data. Psychopharmacology (Berlin) 1997;130:2-13.
38 Modell JG, Mountz JM, Glaser FB, Lee JY. Effect of haloperidol on measures of craving and impaired control in alcoholic subjects. Alcohol Clin Exp Res 1993; 17: 234-240.
39 Manna V. www.salus.it\medicinadelledipendenze\index.htm. 2001.
40 Wickler A. Recent progress in research on the neuro-physiological basis of morphine addiction. Am J Psychiatry 1948;195:329-38.
41 Wikler A, Pescor F. Classical conditioning of a morphine abstincence phenomenon, reinforcement of opioid – drinking behavior and relapse in morphine addicted rats. Psychopharmacologia 1967;10:255-84.
42 Clouet D, Asghar K, Brown R. Mechanisms of cocaine abuse and toxicity. N.I.D.A. Research Monograph 88. Rockville, USA: National Institute on Drug Abuse. 1988.
43 Liberman JM, Cooper SJ. The neuro-pharmacological basis of reward. Oxford: University Press 1989.
44 Carr A, Fibiger HC, Phillips AG. Conditioned place preference as a measure of drug rewards. In: Liberman JM, Cooper SJ, eds. The neuro-pharmacological basis of reward. Oxford: University Press 1989.
45 Di Chiara G, Imperato A. Opposite effects of the K-opiate agonists on dopaminergic-release in the nucleus accumbens and in the dorsal caudate of freely moving rats. J Pharmacol Exp Res 1988;244:1067-80.
46 Carboni E, Imperato A, Perezzani L, Di Chiara G. Amphetamine, cocaine, phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in the nucleus accumbens of freely moving rats. Neuroscience 1988;28:653-61.
47 Martin W, Jasinski D. Physiological parameters of morphine dependence in man-tolerance, early abstinence and protracted abstinence. Psychiatry Res 1969;7:9-17.
48 O’Brien CP, Eherman R, Ternes J. Classical conditioning in human opioid-dependence. In: Goldberg S, Stolerman E, eds. Behavioral analysis of drug dependence. San Diego, California, U.S.A.: Academic Press 1986.
49 Eikelboom R, Stewart J. The conditioning of drug-induced psychological responses. Psychol Rev 1982;89:507-28.
50 Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc National Acad Sci U.S.A. 1988;85:5274-8.
51 Zacny JP, Conley K, Galinkin J. Comparing the subjective, psychomotor and physiological effects of intravenous buprenorphine and morphine in healthy volunteers. J Pharmacol Exp Ther 1997;282:1187-97.
52 Gessa GL, Muntoni F, Collu M, Vargiu L, Mereu GP. Low doses of ethanol activate dopaminergic neurons in the ventral tegmental area. Brain Res 1985;34:210-6.
53 Mereu GP, Woom P, Boi V, Gessa GL, Naesa L, Westerfall TC. Preferential stimulation of ventral tegmental area dopaminergic neurons by nicotine. Europ J Pharmacol 1987;141:393-6.
54 Di Chiara G, Acquas E, Carboni E. Role of mesolimbic dopamine in the motivational effects of drug: brain dialysis and place preference studies. In: Willner P, Sheel-Kruger J, eds. The mesolimbic dopamine system: from motivation to action. Chichester, UK: John Wiley and Sons Publ. 1991.
55 Koob GF, Le HT, Creese I. The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat. Neuroscience Letters 1987;79:315-9.
56 Phillips AG, Pfaus JG, Blaha CD. Dopamine and motivated behavior: insight provided by in vivo analyses. In: Willner P, Sheel-Kruger J, eds. The mesolimbic dopamine system: from motivation to action. Chichester, UK: John Wiley and Sons Publ 1991.
57 Taylor JR, Robbins TW. Enhanced behavioural control by conditioned reinforcers following microinjections of d-amphetamine into the nucleus accumbens. Psychopharmacology 1984;84:405-9.
58 Beninger RJ. The role of dopamine in locomotor activity and learning. Brain Res Rev 1983;6:173-9.
59 Mucha RF. Is the motivational effect of opiate withdrawal reflected by common somatic indices of precipitated withdrawal? A place conditioning study in the rat. Brain Res 1987;418:21-7.
60 Acquas E, Carboni E, Leone P, Di Chiara G. SCH 23390 blocks drug-conditioned place-preference and place-aversion: anhedonia (lack of reward) or apathy (lack of motivation) after dopamine receptor blockade? Psychopharmacology 1989;99:151-4.
61 Wise RA, Bozarth MA. A psychomotor stimulant theory of addiction. Psychol Rev 1987;94:469-75.
62 Koob GF, Bloom FE. Cellular and molecular mechanisms of drug dependence. Science 1988;242:715-6.
63 Shippenberg TS, Herz A. Place preference conditioning reveals the involvement of D1 dopamine receptors in the motivational properties of mu and k-opioid agonists. Brain Res 1987;436:169-74.
64 Peris J, Boyson SJ, Cass WA, Curella P, Dwoskin PL, Larson G, et al. Persistence of neurochemical changes in dopamine systems after repeated cocaine administration. J Pharmacol Exp Ther 1990;253:38-44.
65 Manna V, Di Rienzo AM, Caccianotti B, De Maio MSA. Correlati neuro-biologici delle farmaco-tossicodipendenze. Gazzetta Sanitaria della Daunia 1996;46:72-7.
66 Manna V, Di Rienzo AM, Caccianotti B, De Maio MSA. Neurobiologia delle farmaco-tossicodipendenze. Neurologia, Psichiatria, Scienze Umane 1997;17:367-79.
67 Maremmani I, Canoniero S, Zolesi O. Forme cliniche del craving e farmaci anticraving. Itaca 1999;7:20-39.
68 Manna V, Agnoli A. Aspetti nosografici e biologici delle sindromi depressive: recenti acquisizioni. Giornale di Neuro-Psico-Farmacologia 1983;6:249-60.
69 Selye H. A syndrome produced by diverse noxious agents. Nature 1936;32:138-43.
70 Manna V. Stress, integrazione socio-ambientale e salute mentale nella valutazione multiassiale secondo il DSM-IIIR. Psichiatria e Territorio 1990;7:63-9.
71 Erb S, Shahan Y, Stewart J. Stress reinstates cocaine-seeking behavior after prolonged extinction and a drug free period. Psychopharmacology 1996;128:408-12.
72 Gawin FH, Kleber HD. Abstinence symptomatology and psychiatric diagnosis in cocaine abusers: clinical observations. Arch Gen Psychiatry 1986;43:107-13.
73 Baummeister RF, Heatherton TF, Tice DM. Losing control: how and why people fail at self-regulation. San Diego, California, USA: Academic Press 1994.
74 Markou A, Koob GF. Post-cocaine anhedonia: an animal model of cocaine withdrawal. Neuropsychopharmacology 1991;4:17-26.
75 Parsons LH, Koob GF, Weiss F. Serotonin dysfunction in the nucleus accumbens of rats during withdrawal after unlimited access to intravenous cocaine. J Pharmacol Exp Ther 1995;274:1082-119.
76 Markou A, Koob GF. Construct validity of a self-stimulation threshold paradigm: effects of reward and performance manipulations. Physiol Behav 1992;51:111-19.
77 Wiess F, Markou F, Lorang MT, Koob GF. Basal extra-cellular dopamine levels in the nucleus accumbens are decreased during cocaine withdrawal after unlimited access self-administration. Brain Res 1992;593:314-8.
78 Stinus L, Le Moal M, Koob GF. Nucleus accumbens and amygdala are possible substrates for the aversive stimulus effects of opiate withdrawal. Neuroscience 1990;37:767-73.
79 Roberts A J, Cole M, Koob G F. Intra-amygdala muscimol decreases operant ethanol self-administration in dependent rats. Alcohol Clin Exp Res 1996;20:1289-98.
80 Fitzgerald LW, Nestler EJ. Molecular and cellular adaptation in signal transduction pathways following ethanol exposure. Clin Neurosci 1995;3:165-73.
81 Dani JA, Heineman S. Molecular and cellular aspects of nicotine abuse. Neuron 1996;16:905-8.
82 Kreek MJ. Multiple drug abuse patterns and medical consequences. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press 1987.
83 Koob GF, Heinrich SC, Menzaghi F, Merlo-Pich E, Britton KT. Corticotropin-releasing factor, stress and behavior. Seminars in Neurosciences 1994;6:221-9.
84 Marlatt GA. Relapse prevention: maintenance strategies in the treatment of addictive behaviors. London: Guilford 1985.
85 McKay JR, Rutherford MJ, Alterman AI. An examination of the cocaine relapse process. Drug Alcohol Dependence 1995;38:35-9.
86 Wallace BC. Psycological and environmental determinants of relapse in crack cocaine smokers. J Substance Abuse Treatment 1989;6:95-9.
87 Brown SA, Vik PW, Patterson TL. Stress, vulnerability and adult alcohol relapse. J Studies Alcoholism 1995;56:538-43.
88 Nash J Jr., Maickel RP. The role of the hypothalamic-pituitary-adrenocortical axis in post-stress-induced ethanol consumption by rats. Prog Neuropsychopharmacol Biol Psychiatry 1988;12:653-9.
89 Mollenauer S, Bryson R, Robinson M. ET-OH self-administration in anticipation of noise stress in C57BL/6J mice. Pharmacol Biochem Behav 1993;46:35-9.
90 Higley JD, Hasert MF, Suomi SJ, Linnoila M. Non-human primate model of alcohol consumption. Proc National Acad Sci USA 1991;88:7261-3.
91 Shaham Y, Stewart J. Exposure to mild stress enhances the reinforcing efficacy of intravenous heroin self-administration in rats. Psycopharmacology 1994;111:523-5.
92 Oeders NE, Guerin GF. Non-contingent electric shock facilitates the acquisition of intravenous cocaine self-administration in rats. Psychopharmacology 1994;114:63-9.
93 Haney M, Maccari S, Le Moal M. Social stress increases the acquisition of cocaine self-administration in male and female rats. Brain Res 1995;698:46-51.
94 Ramsey NF, Van Ree M. Emotional but not physical stress enhances intravenous cocaine self-administration in drug naive rats. Brain Res 1993;608:216-9.
95 Shaham Y, Stewart J. Stress reinstates heroin-seeking in drug-free animals: an affect mimicking heroin, not withdrawal. Psycopharmacology 1995;119:334-7.
96 Ahmed SH, Koob GF. Cocaine but not food-seeking behavior is reinstated by stress after extinction. Psychopharmacology 1997;132:289-93.
97 Le AD, Quan B, Juzytch W. Reinstatement of alcohol-seeking by priming injections of alcohol and exposure to stress in rats. Psychopharmacology 1998;135:169-72.
98 Dunn AJ, Berrige CW. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res Rev 1990;15:71-4.
99 Heinrichs SC, Merlo Pich E, Miczek KA. Corticotropin-releasing factor reduces emotionality in socially defeated rats via direct neurotropic action. Brain Res 1992;581:190-3.
100 Swiergiel AH, Takahashi LK, Kalin NH. Attenuation of stress-induced behavior by antagonism of corticotropin-releasing factor receptors in the central amygdala in the rat. Brain Res 1993;623:229-31.
101 Merlo Pich E, Koob GF, Vale W, Weiss F. Release of corticotropin releasing factor (CFR) from the amygdala of ethanol-dependent rats measured with microdialysis. Alcohol Clin Exp Res 1994;18:522-4.
102 Richter RM, Weiss F. In vivo CFR release in rat amygdala is increased during cocaine withdrawal in self-administering rats. Synapse 1999;32:254-7.
103 Rassnick S, Heinrichs SC, Britton KT, Koob GF. Microinjection of a corticotropin-releasing factor antagonist into the central nucleus of the amygdala reverses anxiogenic-like effects of ethanol withdrawal. Brain Res 1993;605:25-9.
104 Heinrichs SC, Menzaghi F, Schulteis G. Suppression of corticotropin - releasing factor in the amygdala attenuates aversive consequences of morphine withdrawal. Behav Pharmacol 1995;6:74-7.
105 Macey DJ, Basso AM, Rivier J. Corticotropin releasing factor (CFR) decreases brain stimulation reward in the rat. Soc Neurosci Abstracts 1997;23:521.
106 Koob GF. Stress, corticotropin-releasing factor and drug addiction. Ann New York Acad Sci 1999;897:27-36.
107 Valdez GR, Zorilla EP, Koob GF, Weiss F. Influence of protracted ethanol abstinence of corticotropin-releasing factor systems and the HPA axis in the dependent rats. Soc Neurosci Abstracts 2000;26:1821.
108 Merlo Pich E, Lorang MT, Yeganeh M. Increase of extracellular corticotropin-releasing factor-like immunoreactivity levels in the amygdala of awake rats during restraint stress and ethanol withdrawal as measured by microdialysis. J Neurosci 1995;15:5439-44.
109 Merlo Pich EM, Koob GF, Heilig M. Corticotropin releasing-factor release from the mediobasal hypothalamus of the rat as measured by microdialysis. Neuroscience 1996;55:695-9.
110 Sarnyai Z, Biro E, Gardi J. Brain corticotropin-releasing factor mediates ‘anxiety-like’ behavior induced by cocaine withdrawal. Brain Res 1995;675:89-94.
111 Zhou Y, Spangler R, La Forge KS. Corticotropin releasing-factor and type 1 corticotropin-releasing factor receptor messenger RNAs in rat brain and pituitary during "binge" cocaine administration and chronic withdrawal. J Pharmacol Exp Ther 1996;279:351-5.
112 Ambrosio E, Sharpe LG, Pilotte NS. Regional binding to corticotropin releasing factor receptors in brain of rats exposed to chronic cocaine and cocaine withdrawal. Synapse 1997;25:272-5.
113 Weiss F, Ciccocioppo R, Parsons LH. Compulsive drug-seeking behavior and relapse. Ann New York Acad Sci 2001;937:1-26.
114 Childres AR, Ehrman RN, McLellan AT, O’Brien CP. Conditioned craving and arousal in cocaine addiction: a preliminary report. In: N.I.D.A. Research Monograph. Washington D.C.: U.S. Government Printing Office. 1988;81:74.
115 Stormark KM, Laberg JC, Bjerland T. Autonomic cued reactivity in alcoholics stimuli. Add Behav 1995;20:571-6.
116 Miller NS, Gold MS. Dissociation of "conscious desire" (craving) from and relapse in alcohol and cocaine dependence. Ann Clin Psychiatry 1994;6:99-105.
117 Tiffany ST, Carter BL. Is craving the source of compulsive drug use? J Psychopharmacol 1998;12:23-6.
118 Weiss F, Maldonado-Vraal CS, Parson H. Control of cocaine-seeking behavior by drug-associated stimuli in rats: affect on recovery of extinguished operant responding and extra cellular dopamine levels in amygdala and nucleus accumbens. Proc Nat Acad Sci USA 2000;97:4321-3.
119 Katner SN, Magalong JG, Weiss F. Reinstatement of alcohol-seeking behavior by drug-associated discriminative stimuli after prolonged extinction in the rat. Neuropsychopharmacology 1999;20:471-6.
120 Katner SN, Weiss F. Ethanol-associated olfactory stimuli reinstate ethanol-seeking behavior after extinction and modify extra cellular dopamine levels in the nucleus accumbens. Alcohol Clin Exp Res 1999;23:1751-5.
121 Gracy KN, Dankiewicz LA, Weiss F, Koob GF. Heroin-specific cues reinstate heroin-seeking behavior in rat after prolonged extinction. Pharmacol Biochem Behav 2000;65:489-95.
122 Weiss F, Ciccocioppo R. Enduring conditioned reactivity to cocaine cues: effects on extinguished operant responding forebrain dopamine release and fos immunoreactivity. Behav Pharmacol 1999;10(Suppl 1):s99-102.
123 Ciccocioppo R, Katner SN, Weiss F. Relapse induced by alcohol-associated environmental stimuli after extinction in rat. Alcohol Clin Exp Res 1999;23(Suppl):52A-55A.
124 Manna V, Tredanari G, Mescia G. Psicogenesi delle farmaco-tossicodipendenze: correlati psicopatologici e prospettive terapeutiche. Salute e Prevenzione 1990;1:63-9.
125 Manna V, Mescia G, Ferrone MC, Giordano MA. Ouroboros, il serpente alchemico. Verso l’integrazione tra psicoterapia e farmacoterapia nel trattamento dei disturbi mentali correlati all’abuso di sostanze. Giornale Italiano di Psicopatologia 1998;2:209-17.
126 Manna V, Ruggiero S. Dipendenze patologiche da sostanze: comorbilità psichiatrica o continuum psicopatologico? Riv Psichiatria 2001;36:1-14.
127 Manna V. Dipendenze patologiche da sostanze e depressione: verso il trattamento integrato multi-modale. Minerva Psichiatrica (in press).
128 Khantzian EJ. The self-medication hypothesis of addictive disorders: focus on heroin and cocaine dependence. Am J Psychiatry 1985;142:1259-64.
129 Wurmser L. Psychoanalytic considerations of the etiology of compulsive drug abuse. Am Psychoanalytic Ass 1974;22:820-43.
130 Rounsaville BJ, Weissman MM, Crits-Christoph K, Wilher K, Kleber H. Diagnosis and symptoms of depression in opiate addicts. Arch Gen Psychiatry 1982;39:151-6.
131 Silvestrini B. Malati di droga. Le sostanze d’abuso: danni fisici e psichici, reazione individuale, difese. Milano: Sperling Kupfer 1995.
132 Naditch MP. Acute adverse reaction to psychoactive drugs, drug use and psychopathology. J Abnormal Psychol 1974;83:394-403.
133 Fabian WD, Fishkin SM. Psychological absorption. Affect investment in marijuana intoxication. J Nerv Mental Disorder 1991;179:39-43.
134 Satel SL, Edell WS. Cocaine-induced paranoia and psychosis proneness. Am J Psychiatry 1991;148:1708-11.
135 de Wit H, Uhlenhuth EH, Pierri J, Johanson CE. Individual differences in behavioral and subjective responses to alcohol. Alcohol Clin Exp Res 1987;11:52-9.
136 Manna V. I precursori psico-sociali e comportamentali dell’abuso di sostanze psico-attive: indagine conoscitiva sulla loro presenza ed importanza relativa nella popolazione scolastica del distretto pugliese n. 31. I Congresso Nazionale Società Italiana per lo Studio dei Comportamenti d’Abuso e delle Dipendenze, S.I.C.A.D., Roma, 7-10 ottobre 1992, Abstracts Book, 1992:159-60.
137 Manna V. Il disagio giovanile come disagio della civiltà: alla ricerca di valori umani autentici nella prospettiva della psicologia transpersonale. Gnosis 1994;7:12-24.
138 Manna V, Mescia G, Ferrone CM, Lattanzio M. I nuovi volti del disagio giovanile. Prospettive di prevenzione sociale in uno studio del Ser.T. della ASL FG/3. Difesa Sociale Rivista dell’Istituto Italiano di Medicina Sociale 1999;1:83-97.
139 Zuckermann M. Sensation seeking, risk taking and health. In: Janisse MP, ed. Individual differences, stress and health. New York: Springer-Verlag 1988.
140 Zuckermann M. Sensation seeking: beyond the optimal level of arousal. Helesdale N.J.: Erlboum 1979.
141 Cloninger CR. A systematic method for clinical description and classification of personality variant. Arch Gen Psychiatry 1987;44:573-88.
142 Cloninger CR, Przybeck TR, Svrakic DM. The Tridimensional Personality Questionnaire: U.S. normative data. Psychol Rep 1991;69:1047-57.
143 Benjamin JLL, Patterson C, Greenberg BD, Murphy DL, Homer DH. Population and familiar association between D4 dopamine receptor gene and measures of NS. National Genetics 1996;12:81-4.
144 Gerra G, Zaimovic A, Timpano M, Zambelli U. Delsignore R, Brambilla F. Neuroendocrine correlates of temperamental traits in humans. Psychoneuroendocrinology 2000;25:479-96.
145 Extein I, Pottash ALC, Gold MS. A possible opioid receptor dysfunction in some depressive disorders. Ann New York Acad Sci 1982;398:110-7.
146 Verebey K. Opioids in mental illness: theories, clinical observations and treatment possibilities. Ann New York Acad Sci 1982;398:125-36.
147 Manna V. L’assordante silenzio della libertà. Appunti per una prevenzione scientificamente orientata del fenomeno droga. Foggia: Leone Ed. 1992.
148 Howard MO, Kivlahan D, Walker RD. Cinger’s tridimensional theory of personality and psychopathology: applications to substance use disorders. J Studies Alcoholism 1997;58:48-66.
149 Block J, Block JH, Keyes S. Longitudinally foretelling drug usage in adolescence: early childhood personality and environmental precursors. Child Development 1988;59:336-55.
150 Pacini M, Maremmani I. Il problema della personalità tossicofilica nella patogenesi del disturbo da uso di sostanze psicoattive. Revisione della Letteratura e recenti acquisizioni. Giornale Italiano di Psicopatologia 2001;7:185-99.
151 Mauri M. Nosografia in evoluzione: i disturbi della condotta alimentare. Giornale Italiano di Psicopatologia 2001;7:109-11.
152 Fairburn CG, Wilson GT. Binge eating: nature, assessment and treatment. New York/London: Guilford Press 1993.
153 Szmukler GL. The epidemiology of anorexia and bulimia. J Psychiatr Res 1985;19:143-53.
154 Fairburn CG, Beglin SG. Studies of epidemiology of bulimia nervosa. Am J Psychiatry 1990;147:401-8.
155 Patton GC. The spectrum of eating disorders in adolescence. J Psychosom Res 1988;32:579-84.
156 Polivy J, Herman CP. Diagnosis and treatment of normal eating. J Consulting Clin Psychol 1987;55:635-44.
157 Striegel-Moore RH. Prevention of bulimia nervosa: questions and challenges. J Psychosomatic Res 1980;24:353-9.
158 Shisslak CM, Crago M, Estess LS. The spectrum of eating disturbances. Intern J Eating Disorders 1995;3:209-19.
159 Mauri MC, Rudelli R, Somaschini E. Neurobiological and psychopharmacological basis in the therapy of bulimia and anorexia. Prog Neuropsychopharmacol Biol Psychiatry 1996;20:207-40.
160 Kaye WH, Gendall K, Strober M. Serotonin neuronal function and selective serotonin reuptake inhibitor treatment in anorexia and bulimia nervosa. Biol Psychiatry 1998;44:825-38.
161 Jimerson DC, Wolfe BE, Brotman AW, Metzger ED. Medications in the treatment of eating disorders. Psychiatr Clin NA 1983;19:739-54.
162 Jimerson DC. The role of central catecholamine pathways in eating disorders. In: Ferrari E, et al. eds. Primary and secondary eating disorders: a psychoneuroendocrine and metabolic approach. Oxford: Pergamon Press 1993.
163 Kaye WH. Central nervous system neuropeptide abnormalities in anorexia and bulimia nervosa. In: Ferrari E, et al. eds. Primary and secondary eating disorders: a psychoneuroendocrine and metabolic approach. Oxford: Pergamon Press 1993.
164 Kaye WH. Neuropeptide abnormalities. In: Halmi KA, ed. Psychobiology and treatment of Anorexia nervosa and Bulimia Nervosa. Washington D.C.: American Psychiatric Press 1992.
165 Halmi KA. Basic biological overview of eating disorders. In: Bloom FE, Kupfer DJ, eds. Psychopharmacology. The fourth generation of progress. New York: Raven Press 1995.
166 Wallin MS, Rissanen AM. Food and mood: relationships between food, serotonin and affective disorders. Acta Psychiatrica Scandinavica 1994;77(Suppl):36-40.
167 Brewerton A. Toward a unified theory of serotonin disturbance in eating and related disorders. Psychoneuroimmunology 1995;20:561-90.
168 Wurtman JJ. Carbohydrate craving. Relationship between carbohydrate intake and disorders of mood. Drugs 1990;39(Suppl 3):49-52.
169 Ericsson M, Carlos Poston WS, Foreyt JP. Common biological pathways in eating disorders and obesity. Addictive Behav 1996;21:733-43.
170 Geracioti TD, Liddle RA, Altemus M. Regulation of appetite and cholecystokinin secretion in anorexia nervosa. Am J Psychiatry 1992;149:958-61.
171 Strober M. Family-genetic perspectives on anorexia and bulimia nervosa. In: Brownwell KD, Fairburn CG, eds. Eating disorders and obesity: a comprehensive handbook. New York: Guilford Press 1995.
172 Hubner HF. Endorphins, eating disorders, and other Addicitive behaviors. New York: Norton & Co. 1993.
173 Jackson EK. Vasopressin and other agents affecting the renal conservation of water. In: Hardman JG, et al. eds. Goodman & Gilman’s the pharmacological Basis of Therapeutics. 9th Ed. New York: McGraw-Hill 1995.
174 Casacchia M, Mela C, Chiaravalle E. Disordini dell’alimentazione. Giornale Italiano di Psicopatologia 2000;6:87-108.
175 Marcus MD. Binge eating and obesity. In: Brownell RD, Fair CG, eds. Eating disorders and obesity. New York/London: Guilford Press 1995.
176 Ricca V, Mannucci E, Di Berardo M, Cabras PL, Rottella CM, Faravelli C. Disturbo da alimentazione incontrollata. Giornale Italiano di Psicopatologia 1998;2:223-39.
177 Apfeldorfer G. Anoressia, Bulimia, Obesità. Milano: Il Saggiatore 1996.
178 Yanoski SZ, Nelson JE, Dubbert BK, Spitzer RL. Association of binge eating disorder and psychiatric comorbidity in obese subjects. Am J Psychiatry 1993;150:1472-9.
179 Loriedo C, Bianchi G, Perrella C. Binge eating disorder: aspetti clinici, nosografici e terapeutici. Giornale Italiano di Psicopatologia 2002;8:92-9.
180 Dwyer DS, Bradley RJ, Kablinger AS, Freeman AM. Glucose metabolism in relation to schizophrenia and antipsychotic drug treatment. Ann Clin Psychiatry 2001;13:103-13.
181 Stanton JM. Weight gain associated with neuroleptic medication: a review. Schizophrenia Bull 1995;21:463-72.
182 Kraepelin E. Die Erscheinungsformen des Irreseins. Zeitschrift für die gesamte. Neurologie Psychiatrie 1920;62:1-29.
183 Crow TJ. The failure of the kraepelinian binary concept and the search for the psychosis gene. In: Kerr A, McClelland H, eds. Concepts of mental disorders. London: Royal College of Psychiatrists 1991.
184 Breier A, Charney DS, Heninger GR. The diagnostic validity of anxiety disorders and their relationship to depressive illness. Am J Psychiatry 1985;142:787-97.
185 Van Praag HM, Asnis GM, Brown SL, Korn M. Beyond serotonin. A multiaminergic perspective on abnormal behavior. In: Brown SL, Van Praag HM, eds. The role of serotonin in psychiatric disorders. New York: Brunner-Mazel Publ. 1991.
186 Van Praag HM. "Make believes" in psychiatry or the perils of progress. New York: Brunner-Mazel Publ. 1993.
187 Bolino F, Di Michele V, Manna V, Di Cicco L, Casacchia M. Information-processing deficits in schizophrenic and schizo-affective disorders. J Psychophysiol 1993;4:348-9.
188 Manna V. La reazione di allerta nei pazienti schizofrenici. Modificazioni dei parametri neurofisiologici e loro significato funzionale. Gazzetta Sanitaria della Daunia 1994;1:40-8.
189 Bolino F, De Michele V, Di Cicco L, Manna V, Daneluzzo E, Casacchia M. Sensorimotor gating ad habituation evoked by electro-cutaneous stimulation in schizophrenia. Biol Psychiatry 1994;36:670-9.
190 Wexler BE. Beyond the kraepelinian dichotomy. Biol Psychiatry 1992;31:539-41.
191 Benkelfat C. Serotoninergic mechanism in psychiatric disorders: new research tools, new ideas. Intern Clin Psychopharmacol 1993;(Suppl 2):53-6.
192 Manna V. Comorbilità psichiatrica delle farmaco-tossicodipendenze. Medicina delle Tossicodipendenze. Organo Ufficiale della Società Italiana Tossicodipendenze 2002;26-7:66-76.
193 Winokur G, Rimmer J, Reich T. Alcoholism. Is there more than one type of alcoholism? Br J Psychiatry 1971;118:525-31.
194 Rounsaville BJ, Kosten TR, Weissman MM. Psychiatric disorders in relatives of probands with opiate addictions. Arch Gen Psychiatry 1991;48:33-42.
195 Manna V, Daniele MT, Pinto M. Psicosi e dipendenze patologiche da sostanze: verso il trattamento integrato multimodale. Giornale Italiano di Psicopatologia 2002;8:36-58.
196 Cibin M. Alcol e disturbi mentali. L’approccio multimodale alla dipendenza alcolica. Psichiatria e Territorio 1996;3:287-97.
197 Manna V, Ferrone MC. Alcol-dipendenza, abuso di sostanze e craving: considerazioni cliniche e proposta di un trattamento integrato multimodale. Bollettino Italiano delle Farmacodipendenze e l’Alcolismo 2001;1:50-61.
198 Mosti A, Giuseppone AR, Montanari L, Giannotti CF. L’attività alcologica in Emilia Romagna: un progetto nato dal basso. Bollettino Italiano delle Farmacodipendenze e Alcolismo 1998;1:21-31.
199 Carey BK. Emerging treatment guidelines for mentally ill chemical abusers. Hospital Community Psychiatry 1989;40:341-9.
200 Osher FC, Kofoed LL. Treatment of patients with psychiatric and psychoactive substance abuse disorders. Hospital Community Psychiatry 1989;40:1025-30.
201 Humphreys K, Moos RH, Hamilton EG. Psychiatric services in VA substance abuse treatment programs. Psychiatr Serv 1996;47:1203-8.
202 Manna V, Lattanzio M. Aspetti diagnostici delle sindromi e dei disturbi associati alle dipendenze patologiche da sostanze. Difesa Sociale. Istituto Italiano di Medicina Sociale 2000;1-2:119-34.